Metadata
Title
Beyond Antibiotics: A Programme Grant funded by the Engineering and Physical Sciences Research Council (EPSRC)
Category
undergraduate
UUID
efd3dcc4b9b94f4489578357115345c7
Source URL
https://beyondantibiotics.ox.ac.uk/
Parent URL
https://eng.ox.ac.uk/our-research
Crawl Time
2026-03-09T03:16:57+00:00
Rendered Raw Markdown

Beyond Antibiotics: A Programme Grant funded by the Engineering and Physical Sciences Research Council (EPSRC)

Source: https://beyondantibiotics.ox.ac.uk/ Parent: https://eng.ox.ac.uk/our-research

The 2019 World Health Organisation (WHO) report on Antimicrobial Resistance (AMR) identifies it as: “one of the greatest threats we face as a global community.” The evolution of drug-resistant bacteria, our over-use of antibiotics and failure to develop new methods for tackling infection could leave us without viable treatments for even the most trivial infections within the next 3 decades.

There have been significant efforts by the WHO and national agencies to raise awareness of AMR and reduce the use of antibiotics, but there is still an urgent need to intensify these efforts and, crucially, to develop alternatives. The aim of the programme is to address this need.

The programme consists of 4 interlinked work packages (WPs) focussed on the core research objectives:

(1) The development of human organoid models for studying interactions between bacteria and the tissue microenvironment and larger scale interactions with the host microbiome.

(2) New microscopy methods to complement the organoid models and to facilitate rapid characterisation of bacteria for improved diagnosis.

(3) New antimicrobial therapeutics and targeted delivery techniques to improve the use of existing antibiotics and provide viable alternatives.

(4) “Drug-free” methods for treating infections and promoting immune function thereby further reducing the use of antibiotics and providing methods suitable for large scale environmental/industrial use.

Funder

UKRI - Engineering and Physical Sciences Research Council (EPSRC). Programme Grant Scheme EP/V026623/1.

Overview of Research

Work Package 1

Work Package 2

Work Package 3

Work Package 4

Work Package 1 focuses on the creation of new platforms for investigating the interactions between bacteria, their microenvironment and therapeutic interventions. Organoid models of the bladder and gut have been established. Biofilms have been grown onto organoid models grown statically and have been evaluated through confocal microscopy and colony-forming unit counting.

Images (left) show microscopic characterisation of a bladder organoid, co-infected with two pathogens.

Work Package 2 focuses on developing microscopy methods for the rapid identification of resistant bacterial strains as an indicator of treatment efficacy. The combination of confocal fluorescence with high-resolution electron microscopy has enabled the three-dimensional structural characterisation of biofilms. Spectroscopic methods have been used to assess biofilm integrity and dispersal.

Image (left) shows bacteria and extracellular matrix fibres forming a biofilm that hinders antibiotic drug delivery.

Work Package 3 investigates methods for improving the delivery of existing and new antimicrobial drugs, including biologic agents to inhibit the development of resistance. Through micro-and nanoencapsulation, new formulations that allow for targeted or stimuli-responsive delivery are being developed.

Image (left) shows a cluster of bacteria after exposure to perfluorocarbon droplets.

Work Package 4 uses ultra-high-speed imaging and acoustic monitoring to optimise exposure conditions and identify suitable treatment monitoring variables to eliminate bacteria and biofilms through physical treatment approaches, such as ultrasound and shockwave exposure. The impact on immune function of physical stimuli is being assessed to determine toxicity and quantify the potential therapeutic value. Hyperspectral imaging is used in combination with ultrasound exposure to monitor biofilm disruption.

Image (left) shows bacterial biofilm following exposure to protein cavitation nuclei.

Research Impacts to Date

NEW: Research published

"Repurposing antimicrobials with ultrasound-triggered nanoscale systems for targeted biofilm drug delivery"

Read more

DRAG

View all News View all Case studies

[30 Jan 2026

Prof Eleanor Stride awarded Freedom of the Worshipful Company of Armourers and Brasiers](https://www.stcatz.ox.ac.uk/catz-fellow-awarded-freedom-of-the-worshipful-company-of-armourers-and-brasiers/)

[15 Dec 2025

Beyond Antibiotics Researcher, Dr Victor Choi, Wins Best Pitch at Conception X 2025 Demo Day](/news/beyond-antibiotics-researcher-dr-victor-choi-wins-best-pitch-at-conception-x-2025-demo-day)

[28 Nov 2025

Addressing Antimicrobial Resistance through Advanced UTI Models](/news/addressing-antimicrobial-resistance-through-advanced-uti-models)

[25 Nov 2025

Beyond Antibiotics Team Members attend event at Royal Society of Medicine on 18 November to tackle AMR](https://www.ineosoxford.ox.ac.uk/news/nobel-prize-now-building-legacy-discovery-tackle-antimicrobial-resistance)

[24 Nov 2025

Innovative nanotechnology is reshaping how we tackle drug-resistant infections](/news/innovative-nanotechnology-is-reshaping-how-we-tackle-drug-resistant-infections)

[21 Nov 2025

Antibiotic pressures can unintentionally fuel the rise of drug-resistant pathogens in the gut](/news/antibiotic-pressures-can-unintentionally-fuel-the-rise-of-drug-resistant-pathogens-in-the-gut)

[19 Nov 2025

Understanding the molecular architecture of biofilms is key to tackling antibiotic tolerance](/news/understanding-the-molecular-architecture-of-biofilms-is-key-to-tackling-antibiotic-tolerance)

[18 Nov 2025

World Antimicrobial Awareness Week 2025](/news/world-antimicrobial-awareness-week-2025)

OrganOx metra: Making more livers usable for transplant

OxLAMP® – accurate and rapid COVID-19 test with no specialist equipment needed

GDm-Health™: Gestational Diabetes management system

OxVent – simple and scalable ventilator

Improving bioreactors used in stem cell therapies

This research is funded by the Engineering and Physical Science Research Council (EPSRC) Programme Grant Scheme under the reference number EP/V026623/1.